The safety of remifentanil administered for up to 5 days in ICU patients with neurotrauma

Detalles Bibliográficos
Autores principales: Stergiopoulos, S, Karabinis, A, Mandragos, K, Komnos, A, Soukup, J, Speelberg, B, Kirkham, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099822/
http://dx.doi.org/10.1186/cc2702
_version_ 1782326554061176832
author Stergiopoulos, S
Karabinis, A
Mandragos, K
Komnos, A
Soukup, J
Speelberg, B
Kirkham, A
author_facet Stergiopoulos, S
Karabinis, A
Mandragos, K
Komnos, A
Soukup, J
Speelberg, B
Kirkham, A
author_sort Stergiopoulos, S
collection PubMed
description
format Online
Article
Text
id pubmed-4099822
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40998222014-09-23 The safety of remifentanil administered for up to 5 days in ICU patients with neurotrauma Stergiopoulos, S Karabinis, A Mandragos, K Komnos, A Soukup, J Speelberg, B Kirkham, A Crit Care Poster Presentation BioMed Central 2004 2004-03-15 /pmc/articles/PMC4099822/ http://dx.doi.org/10.1186/cc2702 Text en
spellingShingle Poster Presentation
Stergiopoulos, S
Karabinis, A
Mandragos, K
Komnos, A
Soukup, J
Speelberg, B
Kirkham, A
The safety of remifentanil administered for up to 5 days in ICU patients with neurotrauma
title The safety of remifentanil administered for up to 5 days in ICU patients with neurotrauma
title_full The safety of remifentanil administered for up to 5 days in ICU patients with neurotrauma
title_fullStr The safety of remifentanil administered for up to 5 days in ICU patients with neurotrauma
title_full_unstemmed The safety of remifentanil administered for up to 5 days in ICU patients with neurotrauma
title_short The safety of remifentanil administered for up to 5 days in ICU patients with neurotrauma
title_sort safety of remifentanil administered for up to 5 days in icu patients with neurotrauma
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099822/
http://dx.doi.org/10.1186/cc2702
work_keys_str_mv AT stergiopouloss thesafetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT karabinisa thesafetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT mandragosk thesafetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT komnosa thesafetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT soukupj thesafetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT speelbergb thesafetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT kirkhama thesafetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT stergiopouloss safetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT karabinisa safetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT mandragosk safetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT komnosa safetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT soukupj safetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT speelbergb safetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma
AT kirkhama safetyofremifentaniladministeredforupto5daysinicupatientswithneurotrauma

Ejemplares similares